AP620A - Uses of a flavin in the treatment of ill-effects caused by viral infections. - Google Patents

Uses of a flavin in the treatment of ill-effects caused by viral infections. Download PDF

Info

Publication number
AP620A
AP620A APAP/P/1994/000695A AP9400695A AP620A AP 620 A AP620 A AP 620A AP 9400695 A AP9400695 A AP 9400695A AP 620 A AP620 A AP 620A
Authority
AP
ARIPO
Prior art keywords
flavin
assay
infection
cells
riboflavine
Prior art date
Application number
APAP/P/1994/000695A
Other languages
English (en)
Other versions
AP9400695A0 (en
Inventor
Ayuko Washington Odur Dr
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of AP9400695A0 publication Critical patent/AP9400695A0/xx
Application granted granted Critical
Publication of AP620A publication Critical patent/AP620A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
APAP/P/1994/000695A 1993-10-19 1994-10-19 Uses of a flavin in the treatment of ill-effects caused by viral infections. AP620A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (2)

Publication Number Publication Date
AP9400695A0 AP9400695A0 (en) 1995-01-31
AP620A true AP620A (en) 1997-10-14

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000695A AP620A (en) 1993-10-19 1994-10-19 Uses of a flavin in the treatment of ill-effects caused by viral infections.

Country Status (26)

Country Link
EP (1) EP0739208A1 (hu)
JP (1) JPH09505804A (hu)
CN (1) CN1140992A (hu)
AP (1) AP620A (hu)
AU (1) AU7943794A (hu)
BG (1) BG100599A (hu)
BR (1) BR9407862A (hu)
CA (2) CA2123825A1 (hu)
CO (1) CO4520283A1 (hu)
CZ (1) CZ113796A3 (hu)
EE (1) EE9600057A (hu)
GB (2) GB9321558D0 (hu)
HR (1) HRP940688A2 (hu)
HU (1) HUT76322A (hu)
IL (1) IL111338A0 (hu)
JO (1) JO1866B1 (hu)
MA (1) MA23356A1 (hu)
MD (1) MD960168A (hu)
NO (1) NO961547L (hu)
OA (1) OA10579A (hu)
PE (1) PE5596A1 (hu)
PL (1) PL314008A1 (hu)
SK (1) SK50696A3 (hu)
UY (1) UY23844A1 (hu)
WO (1) WO1995011028A1 (hu)
ZA (1) ZA948191B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
US11497749B2 (en) * 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
EP0417385A2 (en) * 1989-09-14 1991-03-20 Mitsui Norin Co., Ltd. Preventive and curative medicament against infection with influenza virus, containing tea or tea polyphenols
WO1992017173A2 (fr) * 1991-04-02 1992-10-15 Jean Berque Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
EP0417385A2 (en) * 1989-09-14 1991-03-20 Mitsui Norin Co., Ltd. Preventive and curative medicament against infection with influenza virus, containing tea or tea polyphenols
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
WO1992017173A2 (fr) * 1991-04-02 1992-10-15 Jean Berque Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme

Also Published As

Publication number Publication date
CN1140992A (zh) 1997-01-22
MD960168A (ro) 1998-04-30
HUT76322A (en) 1997-08-28
HU9601006D0 (en) 1996-06-28
NO961547D0 (no) 1996-04-18
EE9600057A (et) 1996-10-15
PE5596A1 (es) 1996-04-18
GB9421099D0 (en) 1994-12-07
IL111338A0 (en) 1994-12-29
EP0739208A1 (en) 1996-10-30
SK50696A3 (en) 1997-01-08
CA2174552A1 (en) 1995-04-27
CO4520283A1 (es) 1997-10-15
BR9407862A (pt) 1997-05-20
GB9321558D0 (en) 1993-12-08
ZA948191B (en) 1995-06-08
CZ113796A3 (en) 1996-11-13
BG100599A (en) 1997-02-28
JO1866B1 (en) 1995-12-27
HRP940688A2 (en) 1997-04-30
NO961547L (no) 1996-06-19
UY23844A1 (es) 1995-03-28
PL314008A1 (en) 1996-08-05
AU7943794A (en) 1995-05-08
JPH09505804A (ja) 1997-06-10
GB2283913A (en) 1995-05-24
AP9400695A0 (en) 1995-01-31
CA2123825A1 (en) 1995-04-20
WO1995011028A1 (en) 1995-04-27
OA10579A (en) 2002-06-19
MA23356A1 (fr) 1995-07-01

Similar Documents

Publication Publication Date Title
US4861759A (en) Antiviral compositions and methods
KR100348775B1 (ko) 면역강화제
JP2018197265A (ja) 新規な葉酸代謝拮抗薬の組み合わせ療法
AP620A (en) Uses of a flavin in the treatment of ill-effects caused by viral infections.
JP3237836B2 (ja) 抗ウイルス医薬組成物
CN101370783B (zh) 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法
EP0183352A2 (en) Use of suramin for clinical treatment of infection with any of the members of the family of human-t-cell leukemia (htvl) viruses including lymphadenopathy virus (lav)
KR20210091758A (ko) Mcl-1 억제제와 미도스타우린의 조합물, 이의 용도 및 약학적 조성물
CZ2001977A3 (cs) Kombinace účinných látek
US5519028A (en) Antiviral preparations
NL194430C (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
Perno et al. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl) adenine to primary macrophages: efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus
KR20150011386A (ko) 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물
US6306901B1 (en) Agent for prophylaxis and therapy of diseases
GB2319474A (en) Anti-viral agents
KR102405447B1 (ko) 5-(2-아마노에틸)-디벤조[cd,f]-인돌-4(5H)-온 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 항 HIV-1용 약학적 조성물
ITMI20131218A1 (it) Nuovi ureido derivati di acidi naftalensolfonici
JP2004530700A (ja) Ａ１アデノシン及びｐ２ｘプリン受容体拮抗薬を使用する方法及び製剤
EP0728002B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
EP0082667A1 (en) Pharmaceutical compositions
EP1518554B1 (en) Pharmaceutical composition for the treatment of hyperhomocysteinemia
US10864210B2 (en) Composition and combined medication method for treating enterovirus infection
JPH08502044A (ja) ヒトウイルス感染の治療
WO2006023073A1 (en) Medical uses of 24-epibrassinolide
DE10228059B4 (de) Verwendung von amphiphilen Nucleosid-Phosphonoameisensäure-Derivaten zur Behandlung von viralen Infektionskrankheiten